Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Metronidazole and interstitial implantation in the treatment of extensive recurrent head and neck cancers. [/sup 192/Ir]

Journal Article · · Cancer; (United States)
OSTI ID:6337298
 [1]; ; ;
  1. Southern California Cancer Center, Los Angeles
Twenty-three patients with recurrent or persistent epidermoid carcinoma of the oral cavity, all of whom had failed primary antitumor therapy, were treated with interstitial irradiation and a radio-sensitizer. All patients underwent afterloading interstitial iridium-192 implants. Each subject received 6 g/m/sup 2/ metronidazole administered orally in one dose every 48 hours for the duration of the implant. The radiation dose ranged between 4500 and 6500 rads in 65 to 120 hours. Sixteen of 23 patients (69.6%) demonstrated complete regression of local disease, usually within 12 weeks. Ten of the 23 individuals (43%) remain alive and disease-free with an average follow-up of 25 months since the completion of the regimen. Neurologic and hepatic toxicity were notably absent. Nausea, mild diarrhea and accentuation of the radiation-induced mucositis constituted the principal side effects.
OSTI ID:
6337298
Journal Information:
Cancer; (United States), Journal Name: Cancer; (United States) Vol. 48:1; ISSN CANCA
Country of Publication:
United States
Language:
English

Similar Records

Short course high fractional dose irradiation in advanced and recurrent head and neck cancer
Conference · Mon Oct 01 00:00:00 EDT 1979 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:5511763

Microwave hyperthermia radiosensitized iridium-192 for recurrent brain malignancy
Journal Article · Mon Feb 29 23:00:00 EST 1988 · Medical Dosimetry; (USA) · OSTI ID:5402289

Brachytherapy of recurrent malignant brain tumors with removable high-activity iodine-125 sources
Journal Article · Sat Dec 31 23:00:00 EST 1983 · J. Neurosurg.; (United States) · OSTI ID:7013012